MAP2K7 and lung carcinoma: Moreover, the reverse expression of SETDB1 and FosB mediated by MEK/ERK2 in anticancer drug therapy may be the potential pathway of cell proliferation, migration, transformation capacity, and diffusion in lung cancer [38,130].